Skip to main content


This article was originally published here

J Pers Med. Aug 28, 2021; 11 (9): 858. doi: 10.3390 / jpm11090858.

ABSTRACT

Gene expression profiling assays such as the Oncotype DX (ODX) 21-gene recurrence score (RS) test are increasingly used in clinical practice to predict the risk of recurrence and to support treatment planning for it. early stage breast cancer (BC). However, this test has certain drawbacks such as high cost and a long time to obtain results, which can lead to disparities in access. Our aim is to identify clinicopathologic factors associated with ODX RS in women with early-stage CB. We conducted a retrospective cohort study of women identified in the medical database of the Deschênes-Fabia Breast Disease Center at the University of Quebec, Canada. Our sample consists of 425 women diagnosed with early stage BC who achieved an ODX RS between January 2011 and April 2015. The ODX RS was classified into three levels as originally defined: low (0-17 ), intermediate (18-30) and high (> 30). The mean RS was 17.8 (SD = 9.2). Univariate analyzes and multinomial logistic regressions were performed to identify factors associated with intermediate and high RS versus low RS. A total of 237 (55.8%) patients had low RS, 148 (34.8%) had intermediate RS and 40 (9.4%) had high RS. Women with negative progesterone receptor (PR) receptors (OR ranging from 3.51 to 10.34) and histologic grade II tumors (OR ranging from 3.16 to 23.04) were consistently more likely to have an intermediate or high RS than a low RS. Similar patterns of associations were seen when the RS was categorized using cutoffs redefined from (i.e. from the TAILORx study or dichotomized). This study provides evidence to suggest that histologic grade and PR status are predictors of intermediate or high SR in women with early-stage BC. If these results are confirmed in future studies, taking these clinicopathological factors into account could prevent women from undergoing such a test before the start of any adjuvant treatment. This option could be considered in contexts where the cost of testing is an issue.

PMID: 34575635 | DOI: 10.3390 / jpm11090858

Leave a Reply